AI biotech Enveda raises $311M to advance nature-derived drug candidates
The Boulder-based company values its AI platform for discovering compounds in nature at $2 billion while testing treatments for skin conditions and weight loss.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 2 articles since 23 Sept 2026. Quartz published first, on 23 September at 14:05 UTC; TechCrunch followed 5h 26m later. The most recent article, from TechCrunch, appeared on 23 September at 19:31 UTC.
Outlets reporting it: TechCrunch (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Enveda